EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The aim of EP0057 - 202 is to assess the safety and efficacy of EP0057 in combination with
Olaparib (a PARP inhibitor) in two cancers where there is a high unmet need: extensive stage
small cell lung cancer (SCLC) and ATM-negative gastric cancer (GC).
EP0057-202 is a non-comparative, multi-arm, multi-centre, open label, Phase 2 study to
determine the efficacy, safety, and tolerability of EP0057 in combination with olaparib (an
approved PARP inhibitor) in defined patient populations with relapsed* GC and SCLC.
*(see Eligibility Criteria for definition of "relapse" for each tumour type/population) The
treatment cohorts will open sequentially at the Sponsor's discretion and patients may be
enrolled into each cohort concurrently.
EP0057 is an investigational nanoparticle-drug conjugate administered intravenously. The
rationale for developing EP0057 is to enable selective entry of EP0057 into tumour tissue and
as a result create preferential accumulation of EP0057, and therefore of the payload
Camptothecin, to translate into maximum tumour cell killing.